Bausch + Lomb: A Blinking Good Investment?

by

So, it appears Caspian Capital, a firm whose name conjures images of vast, slightly chilly seas and possibly a lot of paperwork, has decided to load up on Bausch + Lomb. A cool $21.39 million worth, to be precise. Which, when you think about it, is a lot of contact lens solution. They snagged 1,349,043 shares, a figure that feels oddly specific, as if someone actually counted them. One wonders if they used a small abacus.

What’s the Story?

According to the official filings – and let’s be honest, reading SEC filings is not how most people choose to spend a Saturday afternoon – Caspian Capital increased its Bausch + Lomb holdings. The transaction itself bumped the value of their position by another $21.61 million, a sum that’s likely enough to make a few accountants do a little jig. It’s a decent bet, really. People will always need to see, even if what they’re looking at is just more quarterly reports.

A Bit More Detail (Because There Always Is)

  • Caspian Capital now owns a rather substantial 22.58% of Bausch + Lomb, measured in what they call “AUM” – Assets Under Management. It sounds terribly important, doesn’t it?
  • Here’s a glimpse into their portfolio, for those of us who enjoy a good spreadsheet:
    • NYSE: BLCO: $34.14 million (22.6% of AUM)
    • NASDAQ: FIP: $24.02 million (15.9% of AUM)
    • NASDAQ: FTAI: $21.94 million (14.5% of AUM)
    • NYSE: CCO: $20.50 million (13.6% of AUM)
    • NYSE: PACS: $14.63 million (9.7% of AUM)
  • As of Thursday, Bausch + Lomb shares were trading at $16.87, which is, well, a price. They’ve gone up 11% over the past year, but the S&P 500 is doing rather better, soaring a full 20%. Still, you can’t win them all. And let’s be honest, predicting the stock market is a bit like trying to predict the weather – usually a fool’s errand.

The Basics (In Case You’ve Been Living Under a Rock)

Metric Value
Revenue (TTM) $5.1 billion
Net income (TTM) ($360 million)
Market capitalization $6 billion
Price (as of Thursday) $16.87

What Does Bausch + Lomb Actually Do?

Bausch + Lomb, for those unfamiliar, is a global leader in eye health. They make everything from contact lenses (a modern marvel, really, when you think about it) to surgical devices. They sell to doctors, retailers, and directly to consumers. Basically, if you need something for your eyes, they probably have it. They’ve been at it since 1853, which is a long time – longer than most of us have been blinking, certainly.

So, What Does This Mean for Investors?

Caspian Capital making a big bet on Bausch + Lomb is…interesting. It suggests they see something others don’t, or perhaps they simply have a surplus of capital and a fondness for ophthalmology. The company reported $5.1 billion in revenue last year, a 6% bump from the previous year, and fourth-quarter sales climbed 10% to $1.405 billion. Adjusted EBITDA was $858 million, a slight dip from the year before, but still a respectable number. Growth is being driven by contact lenses, consumer eye health products, and a new dry eye therapy called MIEBO. Apparently, a lot of people have dry eyes. Who knew?

Shares have underperformed the market lately, but they’re roughly in line with it since last quarter. If the company continues to execute, this could be a smart investment. Or it could be a perfectly reasonable way to lose money. Investing, after all, is a gamble, a calculated risk. And sometimes, even the best calculations are wrong. It’s a bit like trying to predict which way the wind will blow. You can make an educated guess, but ultimately, you’re at the mercy of forces beyond your control. And frankly, that’s a little terrifying.

Read More

2026-03-12 20:35